X
Pharma’s new ‘sensible pricing’ behind cancer drug approvals, says NICE
https://pharmaphorum.com/views-and-analysis/pharmas-new-sensible-pricing-behind-cancer-drug-approvals-says-nice/
CDF
A novel UK approach to cancer access: yes, no, or maybe?
Experts discuss the implications of the new, reinvigorated Cancer Drugs Fund, for pharma and patients.
England’s ‘world-first’ cancer database – can it deliver on its promise?
The world’s first national database of cancer treatment outcomes has been launched in England.
What doctors say about changes to the Cancer Drugs Fund
Assessing HCPs’ social media comments about the new approach to cancer drug funding.
NICE says no to liver cancer drug Nexavar
Liver cancer treatment latest earmarked for removal from CDF
Xalkori gains NICE approval after price cut
NICE approval secured against background of renewed controversy
Adcetris falls victim to NICE’s Cancer Drugs Fund clear-out
More CDF legacy products likely to face same fate
Saving the jewel in the crown of ‘UKplc’: Brexit’s impact on pharma
Pharma must embrace the opportunity to shape the UK’s political agenda in its favour.
1 2
